Group by Gene: CD Protein Inhibitors Immune Checkpoint Inhibitors Immunotherapy Interleukins Cyclin Dependent Kinase Inhibitors Serine-Threonine Kinase Inhibitors Chemotherapy DNA Tyrosine Kinase Inhibitors | cisplatin + dacarbazine | DNA synthesis inhibitor cisplatin + temozolomide | temozolomide | toripalimab-tpzi | PD1 inhibitor pembrolizumab | nivolumab | PD1 inhibitor | PD1 inhibitor, CTLA4 inhibitor nivolumab + ipilimumab | IL-2R agonist ALKS 4230 | CDK4 inhibitor, CDK6 inhibitor dalpiciclib | DNA synthesis inhibitor, PD1 inhibitor nivolumab + temozolomide | PDGFR antagonist, mutant c-KIT inhibitor, CSF-1R inhibitor avapritinib | PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor imatinib | CTLA4 inhibitor ipilimumab | pan-RAF inhibitor, Multi-tyrosine kinase inhibitor sorafenib | mTOR inhibitor temsirolimus |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No biomarker | ||||||||||||||||
KIT mutation | ||||||||||||||||
BRAF mutation | ||||||||||||||||
BRAF V600D | ||||||||||||||||
KIT exon 17 mutation | ||||||||||||||||
KIT L576P | ||||||||||||||||
CDK4 amplification | ||||||||||||||||
CTAG1B overexpression | ||||||||||||||||
MAGEA4 overexpression | ||||||||||||||||
MAGEA3 overexpression | ||||||||||||||||
NRAS mutation | ||||||||||||||||
PD-L1 expression | ||||||||||||||||
MDM4 amplification | ||||||||||||||||
EGFR amplification | ||||||||||||||||
MDM2 amplification |